Oxford Biomedica Regulatory News (OXB)

Deferred Bonus Plan Awards

London, UK - 8 May 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group" or "OXB") (LSE:OXB), a leading gene and cell therapy Group, today announces the grant of awards to its executive directors under the Oxford BioMedica 2015 Deferred Bonus Plan ( "DBP") on 7 May 2015.

Under the terms of the DBP, approved by shareholders at the Annual General Meeting on 7 May 2015, the executive directors have been granted awards to cover 50% of their bonus awards for 2014, as disclosed in the 2014 Annual Report. The number of shares subject to each award has been determined by the average closing price of the Company's shares for the five business days up to and including 6 May 2015.

Notes:

1. Includes the 2015 grants described

2. Includes 2014 DBP awards to be met by market purchased shares held by the Oxford BioMedica Employee Benefit Trust

Each award has been granted in the form of a nil-cost option and will become exercisable as to one third of the shares subject to it on each of the first three anniversaries of the grant date.

This notification is made pursuant to Disclosure and Transparency Rule 3.1.4.

- Ends -

Notes for editors

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.